|52Wk High:||52Wk Low:|
VolitionRX Ltd. focuses on the development and commercialization of cancer-detection blood tests for the clinical in-vitro diagnostics and the research-use-only markets. The company's NuQ-X family of blood tests was developed to detect the presence of cancer by detecting nucleosomes containing specific nucleotides. Its NuQ Endo endometriosis test and HyperGenomics tissue- and blood-based tests have been developed to determine the specific subtype of disease and to help decide on the type of therapy. VolitionRX also focuses on the sale of manual and/or semi-automated 96 well enzyme-linked immunosorbent assay plates for use in centralized laboratories, provision of point-of-care devices and disposable home use and doctor's office test systems.